Absci (NASDAQ:ABSI) stockholders approved all proposals presented at the company’s 2026 virtual annual meeting, including the election of two Class II directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
The meeting was led by Sean McClain, Absci’s founder, chief executive officer and director. Zach Jonasson, the company’s chief financial officer and chief business officer, and Shelby Walker, chief legal officer, also participated. Walker recorded the minutes of the meeting.
Quorum Established for Annual Meeting
Andrew N. Wilcox, a representative of Broadridge Financial Solutions Inc., served as inspector of election. According to the operator, 113,355,037 shares were represented either in person or by proxy out of 155,447,428 shares of common stock entitled to vote, establishing a quorum.
Directors Elected
The first item of business was the election of two Class II directors to serve three-year terms. Walker said the company’s board nominated Professor Sir Menelas Pangalos and Daniel Rabinovitsj for election.
Walker said Absci’s bylaws require advance notice from any stockholder intending to nominate directors, and that no such notice had been received. The nominations were then closed. The board unanimously recommended that stockholders vote in favor of the proposal.
The inspector of election reported that a plurality of the shares present or represented and entitled to vote were cast in favor of the nominees.
Ernst & Young Ratified as Auditor
Stockholders also voted to ratify the appointment of Ernst & Young LLP as Absci’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Walker said the audit committee, composed entirely of independent directors, appointed Ernst & Young to audit the company’s financial statements for the fiscal year. She added that stockholder ratification was not required under the company’s bylaws, but that the board submitted the matter as a matter of good corporate governance. If stockholders had not approved the selection, the board and audit committee would have reconsidered the appointment, she said.
The inspector of election reported that a majority of the shares present or represented and entitled to vote supported the ratification of Ernst & Young.
No Stockholder Questions Submitted
After the formal voting matters were completed, McClain said all proposals presented at the meeting had been ratified or approved by stockholders. He said final voting results, including ballots and proxies recorded during the meeting, would be included in the inspector of election’s report, the meeting minutes and the company’s filings with the Securities and Exchange Commission.
Walker said the company had received no questions from stockholders. McClain then adjourned the meeting and thanked stockholders for their support of Absci.
About Absci (NASDAQ:ABSI)
Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.
The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.
